Last reviewed · How we verify
Prevenar 13 + Pneumovax 23
This sequential pneumococcal vaccination regimen primes and boosts the immune system against 13 common pneumococcal serotypes (Prevenar 13) followed by 23 serotypes (Pneumovax 23) to provide broad protection against pneumococcal disease.
This sequential pneumococcal vaccination regimen primes and boosts the immune system against 13 common pneumococcal serotypes (Prevenar 13) followed by 23 serotypes (Pneumovax 23) to provide broad protection against pneumococcal disease. Used for Prevention of invasive pneumococcal disease in adults, Prevention of pneumococcal pneumonia and related infections in high-risk populations.
At a glance
| Generic name | Prevenar 13 + Pneumovax 23 |
|---|---|
| Sponsor | Poitiers University Hospital |
| Drug class | Pneumococcal vaccine combination |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Prevenar 13 is a conjugate vaccine that elicits T-cell dependent immunity against 13 pneumococcal serotypes by linking polysaccharide antigens to a protein carrier. Pneumovax 23 is a polysaccharide vaccine covering 23 serotypes that provides additional coverage. The sequential administration leverages the immunological priming from Prevenar 13 to enhance the response to Pneumovax 23, resulting in superior and more durable protection against invasive pneumococcal disease.
Approved indications
- Prevention of invasive pneumococcal disease in adults
- Prevention of pneumococcal pneumonia and related infections in high-risk populations
Common side effects
- Injection site pain, erythema, or swelling
- Myalgia
- Fatigue
- Headache
- Fever
Key clinical trials
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (PHASE3)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- Clinical Trial of PCV24 in Infants Aged 2-23 Months (PHASE1)
- PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months (PHASE2)
- Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years (PHASE1)
- Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy (PHASE2)
- Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years. (PHASE2)
- Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prevenar 13 + Pneumovax 23 CI brief — competitive landscape report
- Prevenar 13 + Pneumovax 23 updates RSS · CI watch RSS
- Poitiers University Hospital portfolio CI